Comparison · NCT01260688-49e07c8b
Arm I - Cediranib Plus Dasatinib vs Arm II - Cediranib Alone: Treatment Discontinuation Due to Adverse Events (AEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I - Cediranib Plus Dasatinib vs Arm II - Cediranib Alone: Treatment Discontinuation Due to Adverse Events (AEs). Trial comparisons, record NCT01260688-49e07c8b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01260688-49e07c8b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.182 | 0.0514 | 0.477 | wilson | |
| Risk in group 2 | 0.0909 | 0.0162 | 0.377 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0909 | -0.224 | 0.395 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2 | 0.211 | 19 | log | |
| Odds ratio, group 1 over group 2 | 2.22 | 0.171 | 28.9 | log | |
| Number needed to treat, for one more participant with the outcome on Arm I - Cediranib Plus Dasatinib than on Arm II - Cediranib Alone | 11 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I - Cediranib Plus Dasatinib | Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 2 | 11 | OG000 |
| Group 2 | Arm II - Cediranib Alone | Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 1 | 11 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Treatment Discontinuation Due to Adverse Events (AEs)
- Description
- Treatment discontinuation due to Adverse Events
- Time frame
- Through study completion (median duration on study = 4 cycles)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
- NCT number
- NCT01260688
- Phases
- PHASE2
- Conditions
- Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer
- Interventions
- cediranib maleate, dasatinib
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2013-12-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01260688?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01260688-49e07c8b